Skip to Content

Buphenyl (sodium phenylbutyrate) Disease Interactions

There are 3 disease interactions with Buphenyl (sodium phenylbutyrate):

Major

Sodium Phenylbutyrate (Includes Buphenyl) ↔ Fluid Retention

Severe Potential Hazard, High plausibility

Applies to: Congestive Heart Failure, Renal Dysfunction, Fluid Retention

The use of sodium phenylbutyrate may cause fluid retention in patients with congestive heart failure, renal dysfunction, or sodium retention with edema. Sodium phenylbutyrate is primarily excreted by the kidney and these patients may exhibit reduced excretion. Therapy with sodium phenylbutyrate should be administered cautiously in these patients. Monitoring plasma levels of ammonia, arginine, branched-chain amino acids and serum proteins to maintain within normal limits and glutamine to less than 1000 mcmol/L is recommended.

References

  1. "Product Information. Buphenyl (sodium phenylbutyrate)." Horizon Pharma USA Inc, Northbrook, IL.
Major

Sodium Phenylbutyrate (Includes Buphenyl) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Sodium phenylbutyrate is primarily metabolized in the liver and kidney. Therapy with sodium phenylbutyrate should be administered cautiously in patients with liver disease. Monitoring plasma levels of ammonia, arginine, branched-chain amino acids and serum proteins to maintain within normal limits and glutamine to less than 1000 mcmol/L is recommended.

References

  1. "Product Information. Buphenyl (sodium phenylbutyrate)." Horizon Pharma USA Inc, Northbrook, IL.
Moderate

Sodium Phenylbutyrate (Includes Buphenyl) ↔ Neurotoxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: CNS Disorder, Myoneural Disorder, Peripheral Neuropathy

Sodium phenylbutyrate is a pro-drug and is rapidly metabolized to the active, phenylacetate. Neurotoxicity, including exacerbation of a preexisting neuropathy, has been reported with the use of intravenous phenylacetate. The acute onset and reversibility when the phenylacetate infusion was discontinued suggested a drug effect. Care should be exercised when prescribing sodium phenylbutyrate to patients at risk for neurotoxicity.

Buphenyl (sodium phenylbutyrate) drug Interactions

There are 36 drug interactions with Buphenyl (sodium phenylbutyrate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide